MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
International Journal of Gynecological Cancer
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

914 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
914 works in the cohort · of 4,299,418page 11 of 19

Labels cover 3 of 914 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 914 of 914 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Ingrid Boere, Bhavana Pothuri, Olena Sukhina, Tashanna Myers, Valentina Tuninetti, Angeles Alvarez Secord +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Pembrolizumab Or Placebo Plus Adjuvant Chemotherapy With Or Without Radiotherapy In Patients With Newly Diagnosed, High-Risk Endometrial Cancer: Exploratory Analysis Of Disease-Specific Survival From The Phase 3 ENGOT-En11/GOG-3053/KEYNOTE-B21 Study
Michael J. Halaška, Toon Van Gorp, Weiguo Lv, Floor Backes, Fırat Ortaç, Mayu Yunokawa +14 more
2025· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations
Larissa A. Meyer, Shannon N. Westin, Mark Messing, Ellen M. Hartenbach, Michael E. Carney, William E. Bradley +14 more
2025· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
In memorium: C Paul Morrow (1935–2022)
Neville F. Hacker, Peter Heintz, Amodio Denny De Petrillo
2022· letter· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Human Kallikreins (HKS) as Novel Serum Biomarkers in Ovarian Cancer
Dionyssios Katsaros, S. Fracchioli, Irene A. Rigault de la Longrais, M. Puopolo, George M. Yousef, Ignace Vergote +2 more
2003· article· en· International Journal of Gynecological Cancer· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About